List of 8 ALK Inhibitors in trials

List of 8 ALK inhibitor drugs currently in clinical trials:

FDA approved (but several trials ongoing)
Pfizer – Crizotinib (2011 initial, 2013 final)
Novartis – Ceritinib (2014 initial)

FDA Breakthrough Status
Chugai – Alectinib (approved in Japan in 2014)
Ariad AP26113

Ongoing trials
Nerviano NMS-E628. (Licensed by Ignyta and renamed RXDX-101)
Pfizer PF-06463922
Tesaro TSR-011
Xcovery x-396

Discontinued Research
Astellas ASP-3026
Teva CEP-37440

This entry was posted in alectinib - Alecensa from Chugai - Roche - GenenTech, brigatinib-Alunbrig from Takeda, ceritinib - Zykadia from Novartis, crizotinib - Xalkori from Pfizer, Lung cancer, Regulatory applications & approvals, Research, RXDX-101 - entrectinib - by Ignyta, TSR-011 from Tesaro, X-396 - ensartinib from Xcovrery. Bookmark the permalink.

Leave a Reply